title: Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis.
abstract: BACKGROUND
  Moxifloxacin-containing triple therapy has been suggested as an alternative second-line therapy for Helicobacter pylori infection.
  
  
  OBJECTIVE
  To systematically review the efficacy and tolerance of moxifloxacin-containing triple therapy in second-line H. pylori eradication, and to conduct a meta-analysis of studies comparing this regimen with bismuth-containing quadruple therapy.
  
  
  METHODS
  Electronic databases including Medline, Embase, Cochrane controlled trials register, Web of Science, PubMed, Chinese Biomedical Literature Database (updated to December 2010), and manual searches were conducted. A meta-analysis of all randomized controlled trials (RCTs) comparing moxifloxacin-containing triple therapy to bismuth-containing quadruple therapy in the second-line treatment of H. pylori infection was performed.
  
  
  RESULTS
  Seven RCTs including 787 patients were assessed. The meta-analysis showed that the eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (74.9 vs 61.4%, OR 1.89, 95% CI: 1.38-2.58, p < .0001); besides, the rates of side effects and discontinuing therapy because of side effects in the moxifloxacin group were significantly lower than those in the quadruple therapy group (side effects: 10.1 vs 27.8%, OR 0.27, 95% CI: 0.18-0.41, p < .00001; discontinuing therapy because of side effects: 1.4 vs 8.2%, OR 0.18, 95% CI: 0.08-0.40, p < .0001). These results were constant in the sensitivity analyses.
  
  
  CONCLUSIONS
  Moxifloxacin-containing triple regimen is more effective and better tolerated than the bismuth-containing quadruple therapy in the second-line treatment of H. pylori infection.
authors: Department of Digestive Endoscopy, Division of Southern Building, Chinese PLA General Hospital, Beijing, China.
authors: Cheng
authors: C
authors: Wu
authors: Xiao
authors: X
authors: Chen
authors: Jing
authors: J
authors: Liu
authors: Ming-Yang
authors: MY
authors: Li
authors: Zi-Qi
authors: ZQ
authors: Zhang
authors: Zhi-Qiang
authors: ZQ
authors: Wang
mesh_terms: D001372:Aza Compounds / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods*; D024841:Fluoroquinolones; D016481:Helicobacter Infections / Q000188:drug therapy*; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D001729:Bismuth; D000077266:Moxifloxacin